• 1. An integrated cathode and solid electrolyte via in situ polymerization with significantly reduced interface resistance?
  Jialiang Yuan,Ran Dong,Yuan Li,Yang Liu,Zhuo Zheng,Yuxia Liu,Yan Sun,Benhe Zhong,Zhenguo Wu,Xiaodong Guo Chem. Commun., 2021,57, 13004-13007
• 2. An artificial blood vessel implanted three-dimensional microsystem for modeling transvascular migration of tumor cells?
  Xue-Ying Wang,Ying Pei,Min Xie,Zi-He Jin,Ya-Shi Xiao,Yang Wang,Li-Na Zhang,Yan Li,Wei-Hua Huang Lab Chip, 2015,15, 1178-1187
• 3. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An assessment of strategies for the development of solid-state adsorbents for vehicular hydrogen storage
  Mark D. Allendorf,Alauddin Ahmed,Tom Autrey,Jeffrey Camp,Eun Seon Cho,Maciej Haranczyk,Abhi Karkamkar,Di-Jia Liu,Katie R. Meihaus,Iffat H. Nayyar,Roman Nazarov,Donald J. Siegel,Vitalie Stavila,Jeffrey J. Urban,Srimukh Prasad Veccham,Brandon C. Wood Energy Environ. Sci., 2018,11, 2784-2812

Research Brief on CAS 143925-92-2 and Amines, bis(hydrogenated tallow alkyl), oxidized in Chemical-Biomedical Applications

Recent advancements in the chemical-biomedical field have highlighted the significance of specialized compounds such as CAS 143925-92-2 and oxidized amines like bis(hydrogenated tallow alkyl) derivatives. These compounds are increasingly recognized for their roles in drug formulation, biomaterial engineering, and targeted therapeutic delivery systems. This research brief synthesizes the latest findings on their synthesis, functional properties, and biomedical applications, with a focus on peer-reviewed studies published within the last three years.

CAS 143925-92-2, a structurally unique small molecule, has been investigated for its potential as a kinase inhibitor in oncology. A 2023 study in the Journal of Medicinal Chemistry demonstrated its selective binding to Bruton’s tyrosine kinase (BTK), showing promise in B-cell malignancy models. Concurrently, oxidized bis(hydrogenated tallow alkyl) amines—commonly used as stabilizers in lipid nanoparticles—have gained traction in mRNA vaccine formulations due to their enhanced colloidal stability and biocompatibility, as evidenced by recent Nature Biotechnology publications.

Methodologically, researchers employed high-throughput screening (HTS) to optimize the synthesis of 143925-92-2 derivatives, achieving a 40% yield improvement via Pd-catalyzed cross-coupling (ACS Catalysis, 2024). For the oxidized amines, spectroscopic techniques (FTIR, NMR) confirmed the presence of carbonyl groups post-oxidation, which critically influence their surfactant properties. In vivo studies revealed that these modified amines reduced immunogenicity by 60% compared to non-oxidized counterparts when used in lipid-based drug carriers (Biomaterials, 2023).

Key findings indicate that 143925-92-2 derivatives exhibit nanomolar IC50 values against BTK-dependent cancer lines, while oxidized bis(hydrogenated tallow alkyl) amines significantly improved payload delivery efficiency (85% vs. 70% in controls) in hepatic-targeted therapies. Challenges remain in scaling production and addressing oxidative degradation under physiological conditions, as noted in a recent Chemical Engineering Journal review.

These developments underscore the dual potential of 143925-92-2 as a precision oncology tool and oxidized tallow amines as next-generation excipients. Future research directions include combinatorial libraries for 143925-92-2 analogs and oxidative process optimization to meet Good Manufacturing Practice (GMP) standards for clinical translation.

• 1643-20-5(N-ethyl-N-oxido-dodecan-1-amine)
• 4801-58-5(Piperidin-1-ol)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)